secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2023-05-03T23:59:59+00:00
Accession:  0001193125-23-134588
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno completes enrollment in DCCR PWS study; triggers $10M capital infusion
-----------------------------------------------------------------------------

- Enrollment completed in randomized withdrawal period of Study C602 for DCCR in Prader-Willi syndrome.
- Top-line data expected Q3 2023; FDA previously acknowledged data could support an NDA submission.
- Completion triggers $10 million capital infusion from Nantahala, Abingworth, and Vivo per Dec 2022 SPA.
- 77 patients enrolled at 17 US and 5 UK sites; 93% of total 83 patients participated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312523134588/0001193125-23-134588-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312523134588/d363623d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-134588

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer